Mathieu Lane has been appointed chief financial officer of eTheRNA immunotherapies NV as well as president of the Belgian company’s new US subsidiary. Mr Lane has spent more than 15 years in healthcare investment banking in New York, US. His most recent employer was Guggenheim Securities and before that, Bear Stearns. An organic chemist by training, Mr Lane has also worked in lipid-based gene therapy research at Genzyme, now part of Sanofi SA, and at SR One, the venture capital arm of GlaxoSmithKline Plc.
eTheRNA immunotherapies announced the appointment on 27 July 2021.
Copyright 2021 Evernow Publishing Ltd